Journal
NEURODEGENERATIVE DISEASES
Volume 10, Issue 1-4, Pages 305-308Publisher
KARGER
DOI: 10.1159/000334534
Keywords
Statin; A beta clearance; Amyloid precursor protein
Categories
Funding
- Grants-in-Aid for Scientific Research [23390187, 24659349, 21390222] Funding Source: KAKEN
Ask authors/readers for more resources
Background/Aims: Retrospective cohort studies have suggested that statin users have a lower prevalence of dementia. On the other hand, a randomized controlled study failed to show beneficial effects on the cognitive decline in Alzheimer's disease (AD). However, a prospective cohort study demonstrated that users of statins had a lower incidence of AD. One possible interpretation might be that statins could prevent or delay the onset of AD, but not slow cognitive decline once the disease has set in. Given that statins could prevent or delay the onset of AD, what is the responsible mechanism? Methods: We investigated the effect of fluvastatin on A beta metabolism at a clinically relevant dose in mice. Results: Fluvastatin reduced the brain A beta level by increased trafficking of the carboxyl terminal fragment of the amyloid precursor protein (APP-CTF), which was mediated by inhibition of protein isoprenylation. Moreover, the statin reduced the brain A beta level through enhanced A beta clearance mediated by upregulation of low-density lipoprotein receptor-related protein 1 (LRP-1) expression. The statin increased LRP-1 expression, mediated by inhibition of protein isoprenylation. Conclusion: Statins might prevent the onset of AD through reduced A beta production by enhancement of APP-CTF degradation and/or upregulation of A beta clearance. We also showed that promotion of APP-CTF degradation and upregulation of A beta clearance could be modified by a drug, suggesting possible mechanistic targets for disease-modifying drugs. Copyright (C) 2012 S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available